Nalaganje...
Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer
LY3023414 is an oral, selective adenosine triphosphate-competitive inhibitor of class I phosphatidylinositol 3-kinase isoforms, mammalian target of rapamycin, and DNA-protein kinase in clinical development. We report results of a 3 + 3 dose-escalation Phase 1 study for twice-daily (BID) dosing of LY...
Shranjeno v:
| izdano v: | Invest New Drugs |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer US
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7575488/ https://ncbi.nlm.nih.gov/pubmed/32578154 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-020-00968-5 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|